Fierce Biotech White Logo Fierce Biotech White Logo

How Unlocking EHR Data Can Help Improve Our Understanding of Disease Progression Across Diseases

Available on-demand
60 Minutes

Electronic health record (EHR) data collected at the point of care is a unique real-world data source that can be curated to provide powerful insights- often beyond what claims data can do alone. EHR data provides a detailed view into the patient journey and clinician thinking, which is found in unstructured clinician notes. Specialty medical societies play a unique role in their management of qualified clinical data registries, which helps bring together this data — from tens of thousands of healthcare clinicians— at scale.

Join this webinar to understand how structured and unstructured data can be transformed to support life sciences teams with the following:

  • Meeting regulatory requirements
  • Understanding treatment patterns and outcomes
  • Tracking burden of disease
  • Recruiting sites and patients for trials
  • And more!


David Tabano

David Tabano, PhD

David Tabano is a principal health economist leading HEOR efforts for Ophthalmology at Genentech. He conducts RWE generation to support patient access to care. David joined Genentech in 2020 and has diverse experience in the pharmaceutical industry, as well as in public health, managed care organization and state Medicaid organizations. David holds bachelors and masters degrees in Economics, and a PhD in Pharmaceutical Outcomes Research.

Lawrence Whittle

Lawrence Whittle

Lawrence Whittle, President, is responsible for driving the market positioning and customer success at Verana Health. His remit spans a multitude of stakeholders, leading medical society engagement, healthcare clinician experience, and life sciences collaborations, as well as the marketing and quantitative sciences functions to elevate awareness and value across the care continuum.

Lawrence has 25+ years of experience as a senior executive within technology companies spanning different industries, including Data Analytics and Life Sciences. His deep expertise in commercialization includes elevating company positioning, driving sustainable customer value through deep in-market partnerships, and nurturing strong collaborations across all key functions of the business. His experience in early- and mid-stage companies has resulted in two IPOs and two M&A transactions.

Lawrence was born in London and is a true global citizen, having worked across many countries. He has been based in California since 2008.

amir tahami

Amir A. Tahami, M.D., M.Sc., Ph.D.

Amir A. Tahami, M.D., M.Sc., Ph.D., serves as the Global Value & Access Head for Alzheimer’s Disease and Brain Health (ADBH) at Eisai Inc. In this role, he leads and oversees a team responsible for developing and implementing the company’s global market access strategies, health economics and outcomes research, pricing, innovative contracting, and funding solutions for Neurology therapies in the company’s pipeline. 

With over 15 years of experience in the pharmaceutical industry, Dr. Tahami has led global and national teams in defining, developing, and delivering clinical and economic value to stakeholders during early- and late-stage product development. He is dedicated to improving patient care through translating research outcomes into clinical practice and supporting informed decision-making and health policy. Dr. Tahami has been instrumental in the development, launch, and commercialization of over 20 medicines, including multiple blockbusters, across diverse therapeutic areas such as immuno-oncology, immunology, cardiovascular, diabetes, neuroscience, and infectious diseases.

Dr. Tahami is a distinguished physician-scientist and clinical epidemiologist, currently serving as an adjunct professor of Clinical Epidemiology at McGill University and Health Administration at New York University.

Register here to watch on-demand!

60 Minutes